Literature DB >> 3247308

Pharmacodynamics of zoxazolamine and chlorzoxazone in rats.

M Yasuhara1, G Levy.   

Abstract

Zoxazolamine is used for the pharmacologic assessment of possible changes in oxidative enzyme activity (paralysis time test) in rodents, whereas one of its metabolites, chlorzoxazone, is used clinically as a skeletal muscle relaxant. In this investigation, the pharmacodynamics of the two compounds were characterized in normal adult rats to determine their suitability for studies of the kinetics of drug action in disease states. Upon i.v. infusion 5 min beyond the onset of loss of the righting reflex (LRR) and concomitant blood sampling, serum concentrations of either drug were higher at the onset than at the offset of LRR, suggestive of a distribution disequilibrium. When zoxazolamine was infused at three different rates to onset of LRR, the pharmacologic end point was reached in 10 to 53 min. Drug concentrations in serum and brain at onset of LRR increased with increasing infusion rate, whereas drug concentrations in cerebrospinal fluid (CSF) were infusion rate independent and essentially identical to CSF concentrations at offset of LRR. Similar experiments (five infusion rates) with chlorzoxazone revealed drug infusion rate dependence even of CSF concentrations at the onset of LRR; only at very slow infusion rates (onset of effect in greater than or equal to 50 min) were onset concentrations in CSF essentially equal to offset concentrations. Neither drug produced measurable metabolite concentrations in the CSF. It is concluded that zoxazolamine but not chlorzoxazone distributes rapidly between CSF and the biophase, metabolites of either drug do not contribute measurably to the pharmacologic effect, and neither drug is subject to development of functional tolerance under the experimental conditions.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3247308     DOI: 10.1023/a:1015976131643

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

1.  [SPONTANEOUS EEG AND MOTOR REFLEXES OF THE RABBIT UNDER THE INFLUENCE OF CENTRAL RELAXANTS AND NARCOTICS].

Authors:  F HOFFMEISTER
Journal:  Arch Int Pharmacodyn Ther       Date:  1964-04-01

2.  Action of zoxazolamine upon spinal segmental reflexes.

Authors:  L E GEIGER; P CERVONI; J R BERTINO; F MONTELEONE
Journal:  J Pharmacol Exp Ther       Date:  1958-06       Impact factor: 4.030

3.  The renal handling of zoxazolamine (flexin).

Authors:  D Maroske; I M Weiner
Journal:  J Pharmacol Exp Ther       Date:  1968-02       Impact factor: 4.030

4.  Pharmacokinetics of chlorzoxazone in humans.

Authors:  R K Desiraju; N L Renzi; R K Nayak; K T Ng
Journal:  J Pharm Sci       Date:  1983-09       Impact factor: 3.534

5.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

6.  Kinetics of drug action in disease states. IX. Effect of experimental fever on phenobarbital concentrations at onset of loss of righting reflex in rats.

Authors:  M Hisaoka; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1985-03       Impact factor: 4.030

7.  Effect of heparin or salicylate infusion on serum protein binding and on concentrations of phenytoin in serum, brain and cerebrospinal fluid of rats.

Authors:  R C Chou; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1981-10       Impact factor: 4.030

8.  Kinetics of drug action in disease states. XVI. Pharmacodynamics of theophylline-induced seizures in rats.

Authors:  I M Ramzan; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1986-03       Impact factor: 4.030

9.  Physiological disposition and metabolic fate of chlorzoxazone (paraflex) in man.

Authors:  A H CONNEY; J J BURNS
Journal:  J Pharmacol Exp Ther       Date:  1960-04       Impact factor: 4.030

10.  Dose-dependent pharmacokinetics of zoxazolamine in the rat.

Authors:  M Van der Graaff; N P Vermeulen; I E Crul; D D Breimer
Journal:  Drug Metab Dispos       Date:  1986 May-Jun       Impact factor: 3.922

View more
  1 in total

Review 1.  K(Ca)2 channels: novel therapeutic targets for treating alcohol withdrawal and escalation of alcohol consumption.

Authors:  Patrick J Mulholland
Journal:  Alcohol       Date:  2012-03-30       Impact factor: 2.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.